Summit Therapeutics Raises Going Concern Doubt, Says Current Cash Is Insufficient To Fund Operations For The Next 12 Months
Liquidity, Capital Resources and Going Concern Going Concern During the three and six months ended June 30, 2026, we incurred a net loss of $215.7 million and $405.1 million and cash flows used in operating activities
Summit Therapeutics says it doesn't have enough money to keep running for the next year without making big changes. When a company warns about this, it signals serious money problems that investors should watch carefully.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.